辰欣药业
(603367)
| 流通市值：59.99亿 | | | 总市值：59.99亿 |
| 流通股本：4.53亿 | | | 总股本：4.53亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,475,322,404.18 | 1,693,162,287.42 | 850,351,441.43 | 3,444,716,683.93 |
| 营业收入 | 2,475,322,404.18 | 1,693,162,287.42 | 850,351,441.43 | 3,444,716,683.93 |
| 二、营业总成本 | 2,153,057,857.69 | 1,499,927,455.65 | 690,429,639.56 | 3,089,204,509.21 |
| 营业成本 | 1,088,909,322.63 | 769,200,553.71 | 357,361,545.27 | 1,657,342,971.8 |
| 税金及附加 | 34,890,354.69 | 22,498,572.69 | 12,064,153.87 | 45,373,317.4 |
| 销售费用 | 620,810,942.2 | 428,884,678.87 | 196,161,391.41 | 888,219,982.05 |
| 管理费用 | 219,264,666.15 | 136,916,964.9 | 67,949,242.63 | 242,609,231.4 |
| 研发费用 | 201,726,301.98 | 151,829,975.48 | 61,461,848.05 | 285,782,022.86 |
| 财务费用 | -12,543,729.96 | -9,403,290 | -4,568,541.67 | -30,123,016.3 |
| 其中:利息费用 | 240,979.81 | 176,947.43 | 66,593.09 | 1,335,587.2 |
| 其中:利息收入 | 17,911,276.41 | 13,330,001.47 | 7,016,259.94 | 32,616,446.52 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -51,046,681.09 | 30,871,564.66 | -13,177,240.08 | 39,679,633.48 |
| 加:投资收益 | 115,836,976.58 | 91,138,677.54 | 28,213,694.75 | 123,468,458.42 |
| 资产处置收益 | -34,008.91 | 79,144.57 | 87,224.57 | -707,422.32 |
| 资产减值损失(新) | -18,293,227.39 | -36,521,281.08 | -28,091,415.05 | -59,132,365.69 |
| 信用减值损失(新) | -12,764,869.42 | -10,527,847.53 | -8,039,431.17 | -10,186,190.21 |
| 其他收益 | 22,137,204.37 | 17,144,554.98 | 5,332,045.7 | 51,247,530.21 |
| 四、营业利润 | 378,099,940.63 | 285,419,644.91 | 144,246,680.59 | 499,881,818.61 |
| 加:营业外收入 | 1,500,446.37 | 1,013,800.24 | 522,380.75 | 2,653,368.86 |
| 减:营业外支出 | 1,350,561.79 | 1,131,918.05 | 915,018.35 | 6,340,497.34 |
| 五、利润总额 | 378,249,825.21 | 285,301,527.1 | 143,854,042.99 | 496,194,690.13 |
| 减:所得税费用 | 27,486,403 | 18,348,214.62 | 11,742,038.42 | 70,575,825.54 |
| 六、净利润 | 350,763,422.21 | 266,953,312.48 | 132,112,004.57 | 425,618,864.59 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 350,763,422.21 | 266,953,312.48 | 132,112,004.57 | 425,618,864.59 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 347,839,962.17 | 264,430,288.75 | 130,745,202.7 | 421,249,413.74 |
| 少数股东损益 | 2,923,460.04 | 2,523,023.73 | 1,366,801.87 | 4,369,450.85 |
| 扣除非经常损益后的净利润 | 281,608,111.05 | 158,094,392.3 | 116,758,563.01 | 256,314,726.16 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.77 | 0.58 | 0.29 | 0.93 |
| (二)稀释每股收益 | 0.77 | 0.58 | 0.29 | 0.93 |
| 八、其他综合收益 | -1,278,277.75 | -1,278,277.75 | 21,033.62 | 58,501.11 |
| 归属于母公司股东的其他综合收益 | -1,278,277.75 | -1,278,277.75 | 21,033.62 | 58,501.11 |
| 九、综合收益总额 | 349,485,144.46 | 265,675,034.73 | 132,133,038.19 | 425,677,365.7 |
| 归属于母公司股东的综合收益总额 | 346,561,684.42 | 263,152,011 | 130,766,236.32 | 421,307,914.85 |
| 归属于少数股东的综合收益总额 | 2,923,460.04 | 2,523,023.73 | 1,366,801.87 | 4,369,450.85 |
| 公告日期 | 2026-10-28 | 2026-08-25 | 2026-04-29 | 2026-04-03 |
| 审计意见(境内) | | | | 标准无保留意见 |